ArticleBMC pregnancy and childbirth2026
Adverse pregnancy outcomes are associated with cardiovascular and renal dysregulation in late pregnancy.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEmerging evidence links adverse pregnancy outcomes (APOs), including gestational diabetes, pregnancy-induced hypertension (PIH), preterm birth, fetal growth restriction and placental abruption to heightened long-term cardiovascular and renal (CVR) disease risks. CVR dysregulation in late pregnancy may be associated with APOs, but the relationship remains understudied.
objectivesThis study investigated CVR biomarkers alterations in women with APOs, assessed cardiorenal interactions, explored dose-response relationships with APO number, and evaluated independent risk factors. STUDY
designA case-control study was conducted on 340 singleton pregnancies (170 uncomplicated controls, 170 APO cases) at a tertiary maternity hospital in Shanghai. Cardiac hemodynamic markers, including cardiac index (CI) and systemic vascular resistance index (SVRI), were assessed with the USCOM-1 A monitor. Serum levels of cardiac biomarkers (B-type natriuretic peptide [BNP], myoglobin [MYO], creatine kinase isoenzymes [CKMB]) and renal biomarkers (uric acid [UA], blood urea nitrogen [BUN], creatinine [Cr]) were measured, with estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation. Correlation analysis and logistic regression were used; sensitivity analyses excluded PIH and placental abruption.
resultsCompared to controls, APO cases had significantly lower CI, higher SVRI, and elevated BNP, MYO, UA, and BUN (all p < 0.05). Positive linear trends were observed for SVRI, MYO, UA, BUN, and Cr, while negative trends occurred for CI and eGFR, demonstrating a dose-response relationship with increasing APO number. Significant correlations existed between renal (eGFR, Cr) and cardiovascular markers (CI, SVRI), with stronger associations in multiple-APO cases. A positive correlation between eGFR and BNP was observed only in women with two or more APOs (r = 0.283, p = 0.016). Independent risk factors included UA (aOR 4.46, 95%CI 1.39–14.35, p = 0.012), SVRI (aOR 3.58, 95%CI 1.13–11.36, p = 0.03), MYO (aOR 2.50, 95%CI 1.01–6.18, p = 0.046), and pre-pregnancy BMI (aOR 1.08, 95%CI 1.02–1.15, p = 0.007). Sensitivity analysis excluding PIH attenuated most CVR associations, indicating PIH primarily drove the findings.
conclusionOur findings support the value of monitoring CVR biomarkers in late pregnancy to identify women with established or evolving for APOs and suggest potential targets for intervention to mitigate long-term CVR risks. Future longitudinal studies are required to evaluate early-pregnancy predictive potential across APO subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.